Parmir Therapeutics, Inc. is building a pipeline that enables the early diagnosis of Parkinson’s and Alzheimer’s diseases through microRNA-based analysis technology, expanding further into the development of fundamental therapeutics.
Based on our research expertise in Parkinson’s and Alzheimer’s diseases and our proprietary technological capabilities, we are developing in vitro diagnostic kits for early detection and mechanism-based therapeutic agents.
By analyzing changes in blood microRNA expression patterns according to disease onset and progression, we are developing an RT-qPCR–based in vitro diagnostic kit and implementing a molecular diagnostic solution that addresses the limitations of high-cost imaging systems such as PET-CT. Through this, we aim to enable rapid early diagnosis and improve access to screening.
We focus on the pathological mechanisms of the disease and are conducting research aimed at fundamental therapeutics, based on strategies that regulate gene expression and inhibit pathological protein aggregation.
Target disease
Parkinson’s disease and Alzheimer's diseases begin years before symptoms appear. Pamir Therapeutics is researching where it all starts.
R&D
In Vitro Diagnostic(IVD) Kit
We develop a versatile in vitro diagnostic platform by integrating disease-specific microRNA biomarkers with RT-qPCR technology for broad disease applications.
Therapeutics
We target Parkinson's core pathology—gene expression regulation that causes dopamine neuron death and pathological protein aggregation inhibition—to restore normal dopamine system function.
Pipeline
Parmir Therapeutics, Inc. is methodically expanding its phased R&D pipeline—from neurodegenerative disease diagnostic technologies to in vitro diagnostic kits and therapeutics.
